Literature DB >> 21415850

Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells.

S Stamova, M Cartellieri, A Feldmann, C C Bippes, H Bartsch, R Wehner, M Schmitz, M von Bonin, M Bornhäuser, G Ehninger, E P Rieber, M Bachmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21415850     DOI： 10.1038/leu.2011.42

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

1.  Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

Authors:  Christian Kellner; Andreas Günther; Andreas Humpe; Roland Repp; Katja Klausz; Stefanie Derer; Thomas Valerius; Matthias Ritgen; Monika Brüggemann; Jan Gj van de Winkel; Paul Whi Parren; Michael Kneba; Martin Gramatzki; Matthias Peipp
Journal:  Oncoimmunology       Date:  2015-06-05       Impact factor: 8.110

Review 2.  Update on antigen-specific immunotherapy of acute myeloid leukemia.

Authors:  Sarah A Buckley; Roland B Walter
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

3.  Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system.

Authors:  C Arndt; A Feldmann; M von Bonin; M Cartellieri; E-M Ewen; S Koristka; I Michalk; S Stamova; N Berndt; A Gocht; M Bornhäuser; G Ehninger; M Schmitz; M Bachmann
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

Review 4.  NK cells and cancer: you can teach innate cells new tricks.

Authors:  Maelig G Morvan; Lewis L Lanier
Journal:  Nat Rev Cancer       Date:  2016-01       Impact factor: 60.716

5.  A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma.

Authors:  Wing Keung Chan; Siwen Kang; Youssef Youssef; Erin N Glankler; Emma R Barrett; Alex M Carter; Elshafa H Ahmed; Aman Prasad; Luxi Chen; Jianying Zhang; Don M Benson; Michael A Caligiuri; Jianhua Yu
Journal:  Cancer Immunol Res       Date:  2018-05-16       Impact factor: 11.151

Review 6.  Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer.

Authors:  Matthias Peipp; Katja Klausz; Ammelie Svea Boje; Tobias Zeller; Stefan Zielonka; Christian Kellner
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

7.  Characterization of a novel single-chain bispecific antibody for retargeting of T cells to tumor cells via the TCR co-receptor CD8.

Authors:  Irene Michalk; Anja Feldmann; Stefanie Koristka; Claudia Arndt; Marc Cartellieri; Armin Ehninger; Gerhard Ehninger; Michael P Bachmann
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

8.  Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts.

Authors:  R Aliperta; M Cartellieri; A Feldmann; C Arndt; S Koristka; I Michalk; M von Bonin; A Ehninger; J Bachmann; G Ehninger; M Bornhäuser; M P Bachmann
Journal:  Blood Cancer J       Date:  2015-09-18       Impact factor: 11.037

9.  Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype.

Authors:  Christian Kellner; Martin Gramatzki; Matthias Peipp
Journal:  Oncoimmunology       Date:  2013-05-09       Impact factor: 8.110

10.  TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity.

Authors:  Marc Cartellieri; Claudia Arndt; Anja Feldmann; Malte von Bonin; Eva-Maria Ewen; Stefanie Koristka; Irene Michalk; Slava Stamova; Nicole Berndt; Anne Gocht; Martin Bornhäuser; Gerhard Ehninger; Marc Schmitz; Michael Bachmann
Journal:  Oncoimmunology       Date:  2013-10-22       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.